The global market for HER2-Positive Gastric Cancer was valued at US$222.1 Million in 2025 and is projected to reach US$359.9 Million by 2032, growing at a CAGR of 7.1% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Testing for HER2 positivity is conducted using immunohistochemistry (IHC) and confirmed with in situ hybridization (ISH) techniques. Global oncology guidelines recommend HER2 testing in newly diagnosed advanced gastric cancer patients to determine eligibility for HER2-targeted therapy. This has led to increasing integration of molecular profiling into clinical practice, with an emphasis on precision diagnostics to personalize treatment strategies and improve prognosis.
Advanced biologics such as trastuzumab deruxtecan are being tested in patients who are resistant to first-line therapies, showing promise in clinical trials for improved efficacy. Combination therapies that integrate immunotherapy with HER2-targeted drugs are also under evaluation. These innovations reflect a growing pipeline of personalized treatments tailored to HER2 expression profiles and tumor characteristics in gastric cancers.
Stakeholders include oncologists, pathology laboratories, pharmaceutical companies, and diagnostic assay developers. Collaborations between diagnostic firms and drug manufacturers are supporting the development of companion diagnostics and therapy-linked assays. National cancer control programs and public health initiatives are further encouraging HER2 screening as part of broader efforts to improve cancer survival rates through biomarker-driven treatment models.
End-use expansion in oncology treatment centers, diagnostic labs, and personalized drug development programs is strengthening market adoption. Pipeline growth of HER2-directed biologics, extended indications of existing drugs, and supportive clinical guidelines are reinforcing therapeutic relevance. As personalized oncology continues to evolve, HER2 testing and therapy are expected to play a central role in managing a biologically distinct segment of gastric cancer patients.
Global HER2-Positive Gastric Cancer Market - Key Trends & Drivers Summarized
How Is HER2 Positivity Changing the Landscape of Gastric Cancer Diagnosis?
HER2-positive gastric cancer refers to a subset of gastric and gastroesophageal junction cancers that exhibit overexpression of the HER2 (Human Epidermal Growth Factor Receptor 2) protein. While HER2 is more commonly associated with breast cancer, its role in gastric cancer is gaining recognition due to its predictive value for targeted therapy. Accurate diagnosis of HER2 status is now a key step in stratifying patients and guiding treatment regimens, particularly in advanced or metastatic cases.Testing for HER2 positivity is conducted using immunohistochemistry (IHC) and confirmed with in situ hybridization (ISH) techniques. Global oncology guidelines recommend HER2 testing in newly diagnosed advanced gastric cancer patients to determine eligibility for HER2-targeted therapy. This has led to increasing integration of molecular profiling into clinical practice, with an emphasis on precision diagnostics to personalize treatment strategies and improve prognosis.
What Targeted Therapies Are Being Used or Developed for HER2-Positive Gastric Cancer?
Trastuzumab is the most established targeted therapy used for treating HER2-positive gastric cancer. Administered in combination with chemotherapy, it has shown improved survival outcomes in patients with HER2 overexpression. Following its approval for gastric cancer, the scope of HER2-targeted treatments has expanded, with newer agents under investigation including antibody-drug conjugates, bispecific antibodies, and tyrosine kinase inhibitors.Advanced biologics such as trastuzumab deruxtecan are being tested in patients who are resistant to first-line therapies, showing promise in clinical trials for improved efficacy. Combination therapies that integrate immunotherapy with HER2-targeted drugs are also under evaluation. These innovations reflect a growing pipeline of personalized treatments tailored to HER2 expression profiles and tumor characteristics in gastric cancers.
Where Is Demand for Testing and Treatment Growing, and Who Are the Key Stakeholders?
Adoption of HER2 testing and targeted therapy is growing across oncology centers, academic hospitals, and diagnostic laboratories. Demand is strongest in regions with high gastric cancer incidence, such as East Asia, parts of Eastern Europe, and Latin America. Japan, South Korea, and China represent major diagnostic and therapeutic markets due to well-developed cancer care systems and high testing penetration.Stakeholders include oncologists, pathology laboratories, pharmaceutical companies, and diagnostic assay developers. Collaborations between diagnostic firms and drug manufacturers are supporting the development of companion diagnostics and therapy-linked assays. National cancer control programs and public health initiatives are further encouraging HER2 screening as part of broader efforts to improve cancer survival rates through biomarker-driven treatment models.
What Is Driving Growth in the HER2-Positive Gastric Cancer Market?
Growth in the HER2-positive gastric cancer market is driven by several factors including rising incidence of gastric cancer, increasing use of biomarker-based treatment planning, and expanding access to HER2-targeted therapies. Advances in diagnostic precision, including improved antibody-based tests and automated pathology workflows, are supporting accurate HER2 identification.End-use expansion in oncology treatment centers, diagnostic labs, and personalized drug development programs is strengthening market adoption. Pipeline growth of HER2-directed biologics, extended indications of existing drugs, and supportive clinical guidelines are reinforcing therapeutic relevance. As personalized oncology continues to evolve, HER2 testing and therapy are expected to play a central role in managing a biologically distinct segment of gastric cancer patients.
Report Scope
The report analyzes the HER2-Positive Gastric Cancer market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:- Segments: Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Combination Therapies); End-User (Hospitals End-User, Specialty Cancer Centers End-User, Other End-Users)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Chemotherapy segment, which is expected to reach US$156.6 Million by 2032 with a CAGR of a 7.9%. The Targeted Therapy segment is also set to grow at 7.6% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $60.5 Million in 2025, and China, forecasted to grow at an impressive 11.0% CAGR to reach $77.4 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global HER2-Positive Gastric Cancer Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global HER2-Positive Gastric Cancer Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global HER2-Positive Gastric Cancer Market expected to evolve by 2032?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2032?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Acepodia Biotech Inc., Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bellicum Pharmaceuticals and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the companies featured in this HER2-Positive Gastric Cancer market report include:
- Acepodia Biotech Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bavarian Nordic A/S
- Bellicum Pharmaceuticals
- BioInvent International AB
- Bristol-Myers Squibb
- Carisma Therapeutics Inc.
- Celularity Inc.
- Daiichi Sankyo Co., Ltd.
- Genentech (Roche Group)
- GeneQuantum Healthcare
- Hengrui (Jiangsu HengRui Medicine)
- Imugene Limited
- Klus Pharma Inc.
- MacroGenics, Inc.
- Merck & Co., Inc.
- Mersana Therapeutics, Inc.
- Novartis AG
- Pfizer Inc.
- Pieris Pharmaceuticals, Inc.
- Shanghai Miracogen Inc.
- Zymeworks Inc.
What Sets This Report Apart From Others?
- Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
- Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
- Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
- Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
- Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
- Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
SPAIN
RUSSIA
REST OF EUROPE
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acepodia Biotech Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bavarian Nordic A/S
- Bellicum Pharmaceuticals
- BioInvent International AB
- Bristol-Myers Squibb
- Carisma Therapeutics Inc.
- Celularity Inc.
- Daiichi Sankyo Co., Ltd.
- Genentech (Roche Group)
- GeneQuantum Healthcare
- Hengrui (Jiangsu HengRui Medicine)
- Imugene Limited
- Klus Pharma Inc.
- MacroGenics, Inc.
- Merck & Co., Inc.
- Mersana Therapeutics, Inc.
- Novartis AG
- Pfizer Inc.
- Pieris Pharmaceuticals, Inc.
- Shanghai Miracogen Inc.
- Zymeworks Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 281 |
| Published | November 2026 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 222.1 Million |
| Forecasted Market Value ( USD | $ 359.9 Million |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
